US EditionPublished • loading... • Updated
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
The $108 million Series B funding will support elisrasib's global Phase III trials for KRAS G12C-mutant cancers and advance D3 Bio’s targeted oncology pipeline, the company said.
- Dec. 9, 2025, D3 Bio completed a $108 million Series B financing in Shanghai to primarily support the planned global Phase III pivotal program for elisrasib .
- The company's discovery platforms leverage proprietary clinical insight and biomarker strategies and global rights for programs to advance targeted and immuno-oncology programs internationally.
- The financing round was backed by investors including IDG Capital and SongQing Capital, with contributions from WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi and Medicxi, highlighting wide investor confidence.
- This financing enables advancement of elisrasib into late-stage trials and highlights unique potential for patients with KRAS G12C‑mutant cancers.
- Backed by established investors, robust involvement from new and current investors highlights widespread confidence in D3 Bio's innovative pipeline targeting driver mutations and critical immune pathways with first‑in‑class or best‑in‑class potential.
Insights by Ground AI
59 Articles
59 Articles
The Berkshire Eagle+57 Reposted by 57 other sources
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round.
Coverage Details
Total News Sources59
Leaning Left7Leaning Right6Center12Last UpdatedBias Distribution48% Center
Bias Distribution
- 48% of the sources are Center
48% Center
L 28%
C 48%
R 24%
Factuality
To view factuality data please Upgrade to Premium
